Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jul 23, 2026, 7:34 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 204 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Mild-Moderate Alzheimer's Disease Clear all
Recruiting Phase 1 Interventional

Autologous Activated Adipose-derived Stem Cells (RB-ADSC) Injected Directly Into the Brain for Mild to Moderate Alzheimer's Disease

NCT05667649
View directory record Official record
Conditions
Alzheimer Disease
Interventions
RB-ADSC
Biological
Lead sponsor
Regeneration Biomedical, Inc.
Industry
Eligibility
45 Years to 80 Years
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
1
States / cities
Newport Beach, California
Source: ClinicalTrials.gov public record
Updated Apr 3, 2025 · Synced Jul 23, 2026, 7:34 PM EDT
Completed Phase 2 Interventional Results available

Brain Imaging Study Of Rosiglitazone Efficacy And Safety In Alzheimer's Disease

NCT00265148
View directory record Official record
Conditions
Alzheimer's Disease
Interventions
Rosiglitazone, Placebo
Drug · Other
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
50 Years to 85 Years
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2008
U.S. locations
9
States / cities
Litchfield Park, Arizona • Phoenix, Arizona • Scottsdale, Arizona + 6 more
Source: ClinicalTrials.gov public record
Updated Nov 17, 2020 · Synced Jul 23, 2026, 7:34 PM EDT
Terminated Phase 3 Interventional Results available

Study Evaluating the Safety and Efficacy of Bapineuzumab in Alzheimer Disease Patients

NCT00676143
View directory record Official record
Conditions
Alzheimer Disease
Interventions
bapineuzumab, placebo
Drug
Lead sponsor
Pfizer
Industry
Eligibility
50 Years to 88 Years
Enrollment
1,100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2012
U.S. locations
111
States / cities
Birmingham, Alabama • Goodyear, Arizona • Phoenix, Arizona + 54 more
Source: ClinicalTrials.gov public record
Updated Jun 9, 2016 · Synced Jul 23, 2026, 7:34 PM EDT
Completed Phase 4 Interventional

EARTH 413: A Study of Aricept in Hispanic Patients With Mild to Moderate Alzheimer's Disease (AD)

NCT00230568
View directory record Official record
Conditions
Alzheimer's Disease
Interventions
Aricept
Drug
Lead sponsor
Eisai Inc.
Industry
Eligibility
50 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
35
States / cities
Phoenix, Arizona • El Centro, California • Los Angeles, California + 27 more
Source: ClinicalTrials.gov public record
Updated Mar 31, 2011 · Synced Jul 23, 2026, 7:34 PM EDT
Completed Not applicable Interventional Results available

Magnesium L-Threonate for the Enhancement of Learning and Memory in People With Dementia

NCT02210286
View directory record Official record
Conditions
Dementia, Alzheimer's Disease
Interventions
Magtein
Dietary Supplement
Lead sponsor
Stanford University
Other
Eligibility
60 Years and older
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Feb 1, 2021 · Synced Jul 23, 2026, 7:34 PM EDT
Recruiting Phase 3 Interventional

A Study to Evaluate the Efficacy and Safety of KarXT + KarX-EC for Cognitive Impairment in Alzheimer's Disease (MINDSET 2)

NCT06976203
View directory record Official record
Conditions
Alzheimer's Disease
Interventions
KarXT, KarX-EC, Placebo
Drug · Other
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
60 Years to 85 Years
Enrollment
586 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
30
States / cities
Fullerton, California • Irvine, California • Los Angeles, California + 27 more
Source: ClinicalTrials.gov public record
Updated Jul 16, 2026 · Synced Jul 23, 2026, 7:34 PM EDT
Recruiting Phase 3 Interventional

A Study to Evaluate the Efficacy and Safety of KarXT + KarX-EC for Cognitive Impairment in Alzheimer's Disease

NCT06976216
View directory record Official record
Conditions
Alzheimer's Disease
Interventions
KarXT, KarX-EC, Placebo
Drug · Other
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
60 Years to 85 Years
Enrollment
586 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
28
States / cities
Long Beach, California • Redlands, California • Basalt, Colorado + 24 more
Source: ClinicalTrials.gov public record
Updated Jun 25, 2026 · Synced Jul 23, 2026, 7:34 PM EDT
Completed Phase 1 Interventional Results available

A Study of LY3002813 in Participants With Memory Damage Due to Alzheimer's Disease (AD) or AD

NCT02624778
View directory record Official record
Conditions
Alzheimer Disease
Interventions
LY3002813, Placebo
Biological · Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
50 Years and older
Enrollment
61 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
6
States / cities
Delray Beach, Florida • Orlando, Florida • The Villages, Florida + 3 more
Source: ClinicalTrials.gov public record
Updated Oct 7, 2024 · Synced Jul 23, 2026, 7:34 PM EDT
Completed Phase 2 Interventional Results available

A Study Of PF-04447943 Compared To Placebo In Subjects With Mild To Moderate Alzheimer's Disease

NCT00930059
View directory record Official record
Conditions
Alzheimer's Disease
Interventions
PF-04447943, Placebo
Drug
Lead sponsor
Pfizer
Industry
Eligibility
55 Years to 85 Years
Enrollment
191 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
22
States / cities
Northport, Alabama • Costa Mesa, California • Glendale, California + 18 more
Source: ClinicalTrials.gov public record
Updated Nov 18, 2020 · Synced Jul 23, 2026, 7:34 PM EDT
Completed Phase 3 Interventional

A Safety and Efficacy Study of Oral Dimebon in Patients With Mild-To-Moderate Alzheimer's Disease

NCT00675623
View directory record Official record
Conditions
Alzheimer's Disease
Interventions
Dimebon, Placebo
Drug
Lead sponsor
Medivation, Inc.
Industry
Eligibility
50 Years and older
Enrollment
598 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2008
U.S. locations
28
States / cities
Phoenix, Arizona • Costa Mesa, California • Fresno, California + 25 more
Source: ClinicalTrials.gov public record
Updated Sep 26, 2016 · Synced Jul 23, 2026, 7:34 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Feasibility Study in Subjects With Mild to Moderate Alzheimer's Disease

NCT02560753
View directory record Official record
Conditions
Alzheimer's Disease
Interventions
T3D-959
Drug
Lead sponsor
T3D Therapeutics, Inc.
Industry
Eligibility
50 Years to 90 Years
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
3
States / cities
Delray Beach, Florida • Miami, Florida • Charlotte, North Carolina
Source: ClinicalTrials.gov public record
Updated Jul 29, 2018 · Synced Jul 23, 2026, 7:34 PM EDT
Terminated Phase 1 Interventional Accepts healthy volunteers Results available

A Study of LY2599666 in Healthy Participants and Participants With Mild Cognitive Impairment or Alzheimer's Disease (AD)

NCT02614131
View directory record Official record
Conditions
Healthy, Alzheimer's Disease, Mild Cognitive Impairment
Interventions
LY2599666, Solanezumab, Placebo SC, Placebo IV
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
20 Years and older
Enrollment
50 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2016
U.S. locations
3
States / cities
Glendale, California • Marlton, New Jersey • Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Jun 16, 2020 · Synced Jul 23, 2026, 7:34 PM EDT
Completed Phase 2 Interventional

Safety and Efficacy of MEM 1003 Versus Placebo in Patients With Mild to Moderate Alzheimer's Disease

NCT00257673
View directory record Official record
Conditions
Alzheimer's Disease
Interventions
MEM 1003, Placebo for MEM 1003
Drug
Lead sponsor
Memory Pharmaceuticals
Industry
Eligibility
50 Years to 90 Years
Enrollment
183 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
57
States / cities
Northport, Alabama • Mesa, Arizona • Phoenix, Arizona + 51 more
Source: ClinicalTrials.gov public record
Updated May 5, 2008 · Synced Jul 23, 2026, 7:34 PM EDT
Completed Phase 1 Interventional

A Randomized, Double-blind, Placebo-controlled, Combined Single Ascending Dose and Multiple Ascending Dose Study

NCT01230853
View directory record Official record
Conditions
Alzheimer's Disease
Interventions
Active Comparator: A, Placebo Comparator B, Active Comparator B, Placebo Comparator A
Drug
Lead sponsor
Eisai Inc.
Industry
Eligibility
50 Years and older
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
8
States / cities
Garden Grove, California • San Francisco, California • Orlando, Florida + 5 more
Source: ClinicalTrials.gov public record
Updated Nov 22, 2020 · Synced Jul 23, 2026, 7:34 PM EDT
Terminated Phase 2 Interventional Results available

A Long Term Extension Study Evaluating ACC-001 With QS-21 in Subjects With Mild to Moderate Alzheimer's Disease

NCT00960531
View directory record Official record
Conditions
Alzheimer Disease
Interventions
ACC-001+ QS21 (3mcg), ACC-001 (10 mcg) + QS-21, ACC-001+QS-21 (30mcg)
Biological
Lead sponsor
Pfizer
Industry
Eligibility
50 Years to 85 Years
Enrollment
160 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2013
U.S. locations
28
States / cities
Phoenix, Arizona • Sun City, Arizona • San Francisco, California + 10 more
Source: ClinicalTrials.gov public record
Updated Mar 31, 2016 · Synced Jul 23, 2026, 7:34 PM EDT
Completed Phase 3 Interventional

To Evaluate the Safety and Effectiveness of Atorvastatin Plus a Cholinesterase Inhibitor in AD Patients.

NCT00151502
View directory record Official record
Conditions
Alzheimer's Disease
Interventions
Atorvastatin
Drug
Lead sponsor
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Industry
Eligibility
50 Years to 90 Years
Enrollment
600 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2007
U.S. locations
40
States / cities
Sun City, Arizona • Fresno, California • Laguna Hills, California + 35 more
Source: ClinicalTrials.gov public record
Updated Feb 17, 2021 · Synced Jul 23, 2026, 7:34 PM EDT
Completed Phase 3 Interventional

ALADDIN Study - Phase III: Antigonadotropin-Leuprolide in Alzheimer's Disease Drug INvestigation (VP-AD-301)

NCT00231946
View directory record Official record
Conditions
Alzheimer's Disease
Interventions
VP4896
Drug
Lead sponsor
Voyager Pharmaceutical Corporation
Industry
Eligibility
60 Years and older
Enrollment
555 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2005
U.S. locations
55
States / cities
Peoria, Arizona • Tucson, Arizona • Fresno, California + 49 more
Source: ClinicalTrials.gov public record
Updated Sep 19, 2007 · Synced Jul 23, 2026, 7:34 PM EDT
Terminated Phase 2Phase 3 Interventional Results available

Open Label Study of ATH-1017 for Treatment of Mild to Moderate Alzheimer's Disease

NCT04886063
View directory record Official record
Conditions
Alzheimer Disease
Interventions
ATH-1017
Drug
Lead sponsor
LeonaBio
Industry
Eligibility
55 Years to 85 Years
Enrollment
423 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
1
States / cities
Rochester, New York
Source: ClinicalTrials.gov public record
Updated Mar 31, 2025 · Synced Jul 23, 2026, 7:34 PM EDT
Completed Phase 2 Interventional Results available

A Long-Term Safety Extension of Studies ABE4869g and ABE4955g in Participants With Mild to Moderate Alzheimer's Disease Treated With Crenezumab

NCT01723826
View directory record Official record
Conditions
Alzheimer's Disease
Interventions
Crenezumab
Drug
Lead sponsor
Genentech, Inc.
Industry
Eligibility
50 Years and older
Enrollment
360 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2017
U.S. locations
47
States / cities
Phoenix, Arizona • Scottsdale, Arizona • Sun City, Arizona + 42 more
Source: ClinicalTrials.gov public record
Updated Feb 19, 2020 · Synced Jul 23, 2026, 7:34 PM EDT
Completed Phase 3 Interventional

Bapineuzumab in Patients With Mild to Moderate Alzheimer's Disease (ApoE4 Non-Carrier)

NCT00574132
View directory record Official record
Conditions
Alzheimer's Disease
Interventions
Bapineuzumab 0.5 mg/kg, Placebo Control, Bapineuzumab 1.0 m/kg
Drug
Lead sponsor
JANSSEN Alzheimer Immunotherapy Research & Development, LLC
Industry
Eligibility
50 Years to 88 Years
Enrollment
1,331 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2012
U.S. locations
219
States / cities
Birmingham, Alabama • Goodyear, Arizona • Phoenix, Arizona + 170 more
Source: ClinicalTrials.gov public record
Updated Nov 24, 2013 · Synced Jul 23, 2026, 7:34 PM EDT
Completed Phase 2Phase 3 Interventional Results available

A Dose-ranging Study to Investigate Efficacy of Buntanetap in Mild to Moderate AD

NCT05686044
View directory record Official record
Conditions
Alzheimer Disease
Interventions
Buntanetap/Posiphen, Placebo
Drug
Lead sponsor
Annovis Bio Inc.
Industry
Eligibility
55 Years to 85 Years
Enrollment
351 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
54
States / cities
Gilbert, Arizona • Phoenix, Arizona • Fort Smith, Arkansas + 42 more
Source: ClinicalTrials.gov public record
Updated Apr 28, 2025 · Synced Jul 23, 2026, 7:34 PM EDT
Terminated Phase 2 Interventional Results available

Dose-Finding Study To Evaluate Safety, Tolerability, and Efficacy of E2609 in Participants With Mild Cognitive Impairment Due to Alzheimer's Disease (Prodromal Alzheimer's Disease) and Mild to Moderate Dementia Due to Alzheimer's Disease

NCT02322021
View directory record Official record
Conditions
Alzheimer Disease, Dementia, Alzheimer Type
Interventions
E2609, Placebo
Drug
Lead sponsor
Eisai Inc.
Industry
Eligibility
50 Years to 85 Years
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2019
U.S. locations
21
States / cities
Bellflower, California • Costa Mesa, California • Glendale, California + 18 more
Source: ClinicalTrials.gov public record
Updated Mar 4, 2021 · Synced Jul 23, 2026, 7:34 PM EDT
Completed Phase 3 Interventional

Safety and Efficacy Study Evaluating TRx0237 in Subjects With Mild to Moderate Alzheimer's Disease

NCT01689246
View directory record Official record
Conditions
Alzheimer's Disease
Interventions
TRx0237 150 mg/day, TRx0237 250 mg/day, Placebo
Drug
Lead sponsor
TauRx Therapeutics Ltd
Industry
Eligibility
Up to 89 Years
Enrollment
891 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
26
States / cities
Phoenix, Arizona • Laguna Hills, California • Los Angeles, California + 23 more
Source: ClinicalTrials.gov public record
Updated Mar 13, 2018 · Synced Jul 23, 2026, 7:34 PM EDT
Completed Phase 2 Interventional

AAB-001 in Patients With Mild to Moderate Alzheimer's Disease

NCT00112073
View directory record Official record
Conditions
Alzheimer's Disease
Interventions
bapineuzumab, placebo
Drug · Other
Lead sponsor
JANSSEN Alzheimer Immunotherapy Research & Development, LLC
Industry
Eligibility
50 Years to 85 Years
Enrollment
234 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2008
U.S. locations
26
States / cities
Sun City, Arizona • Irvine, California • Los Alamitos, California + 23 more
Source: ClinicalTrials.gov public record
Updated Mar 13, 2012 · Synced Jul 23, 2026, 7:34 PM EDT